Literature DB >> 8292883

The effect of recombinant human erythropoietin on cardiovascular responses to postural stress in dialysis patients.

M E Rogerson1, C H Kong, B Leaker, F D Thompson, E Oviasu, G H Neild.   

Abstract

The normal response to 45 degrees head-up tilt (decreased stroke volume and cardiac output and increased heart rate and peripheral resistance) is not seen in the majority of haemodialysis patients. This is due to both an abnormal baroreceptor reflex and increased venous tone which may be explained by a number of factors including hypoxia, acidosis and sodium retention. We have studied this response by impedance cardiography in eight chronic haemodialysis patients, both before and after 3 months of treatment with human recombinant erythropoietin. Before treatment the cardiovascular parameters were abnormal both at rest and on tilting in each patient. The change in each measurement following tilting was: stroke volume, 0.5 +/- 6%; cardiac output, 6 +/- 5%; peripheral resistance, -8 +/- 4%; and heart rate, 10 +/- 4%. After 3 months of erythropoietin (150 U/kg/week intravenously) the mean haematocrit had risen from 19.5 +/- 3% to 32.9 +/- 4% and all patients felt physically fitter. Impedance showed no change in the supine-indices but after tilting there was a dramatic fall in stroke volume (-26 +/- 7%) and cardiac output (-17 +/- 7%) and an increase in heart rate (15 +/- 4%) and peripheral resistance (28 +/- 10%) each moving towards the normal response. These results indicate that human recombinant erythropoietin normalizes the response to postural stress in these patients and suggest that anaemia is the principal cause of the abnormal venoconstriction seen in haemodialysis patients. The mechanisms involved warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8292883     DOI: 10.1007/BF01829017

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  12 in total

1.  Effect of 2 liters of intraperitoneal dialysate on the cardiovascular system.

Authors:  C H Kong; U Raval; F D Thompson
Journal:  Clin Nephrol       Date:  1986-09       Impact factor: 0.975

2.  The Minnesota impedance cardiograph- theory and applications.

Authors:  W G Kubicek; J Kottke; M U Ramos; R P Patterson; D A Witsoe; J W Labree; W Remole; T E Layman; H Schoening; J T Garamela
Journal:  Biomed Eng       Date:  1974-09

3.  Erythropoietin does not induce vasoconstriction directly in human subcutaneous resistance arterioles.

Authors:  S J Bund; A Heagerty; M Edmunds; J Walls
Journal:  Nephron       Date:  1989       Impact factor: 2.847

Review 4.  Differential systemic arterial and venous actions and consequent cardiac effects of vasodilator drugs.

Authors:  R R Miller; W H Fennell; J B Young; A R Palomo; M A Quinones
Journal:  Prog Cardiovasc Dis       Date:  1982 Mar-Apr       Impact factor: 8.194

5.  Mechanisms of autonomic nervous system dysfunction in uremia.

Authors:  V M Campese; M S Romoff; D Levitan; K Lane; S G Massry
Journal:  Kidney Int       Date:  1981-08       Impact factor: 10.612

6.  Effect of different degrees of tilt on cardiac output, heart rate, and blood pressure in normal man.

Authors:  J Tuckman; J Shillingford
Journal:  Br Heart J       Date:  1966-01

7.  Endothelin-1 contracts isolated vessels independently of dihydropyridine-sensitive Ca2+ channel activation.

Authors:  P D'Orleans-Juste; G De Nucci; J R Vane
Journal:  Eur J Pharmacol       Date:  1989-06-20       Impact factor: 4.432

8.  Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels.

Authors:  S Heidenreich; K H Rahn; W Zidek
Journal:  Kidney Int       Date:  1991-02       Impact factor: 10.612

9.  Role of the vascular endothelium in regulating the response of small arteries of the dog kidney to transmural pressure elevation and reduced PO2.

Authors:  H Eskinder; D R Harder; J H Lombard
Journal:  Circ Res       Date:  1990-05       Impact factor: 17.367

10.  Hemodynamic responses to head-up tilt in uremic patients.

Authors:  C H Kong; F D Thompson
Journal:  Clin Nephrol       Date:  1990-06       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.